The peroxisome proliferator-activated receptor alpha (PPARalpha) agonist ciprofibrate inhibits apolipoprotein B mRNA editing in low density lipoprotein receptor-deficient mice: effects on plasma lipoproteins and the development of atherosclerotic le
about
Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasisCiprofibrate therapy in patients with hypertriglyceridemia and low high density lipoprotein (HDL)-cholesterol: greater reduction of non-HDL cholesterol in subjects with excess body weight (The CIPROAMLAT study)RNA Editing-Systemic Relevance and Clue to Disease Mechanisms?Activation of peroxisome proliferator-activated receptor alpha increases the expression and activity of microsomal triglyceride transfer protein in the liverMetabolic regulation of APOBEC-1 complementation factor trafficking in mouse models of obesity and its positive correlation with the expression of ApoB protein in hepatocytesPPARα-Deficient ob/ob Obese Mice Become More Obese and Manifest Severe Hepatic Steatosis Due to Decreased Fatty Acid Oxidation.ApoB-100-containing lipoproteins are major carriers of 3-iodothyronamine in circulation.Ciprofibrate increases paraoxonase activity in patients with metabolic syndrome.Liraglutide prevents hypoadiponectinemia-induced insulin resistance and alterations of gene expression involved in glucose and lipid metabolismMechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet.3,5,3'-Triiodo-L-Thyronine- and 3,5-Diiodo-L-Thyronine- Affected Metabolic Pathways in Liver of LDL Receptor Deficient Mice.PPARs as therapeutic targets in cardiovascular disease.Therapy with Astragalus polysaccharides rescues lipotoxic cardiomyopathy in MHC-PPARα mice.PPARalpha activation increases triglyceride mass and adipose differentiation-related protein in hepatocytes.
P2860
Q24541529-C422F890-341E-4CC4-8605-D0E9AE0BB575Q24796775-7E9737DB-63BA-4BFC-88DE-C8C3AFAFF307Q28079613-62569A4F-670F-482C-B77F-972F2117EC7CQ28570588-B2586DC4-1A44-4BEB-86AE-30499542D498Q28590303-9B2AE0A2-B3B8-4E2A-A0A5-7F704AD9D765Q35568081-F090A427-7004-4B37-B0A8-3A385689DD70Q35693962-C4E58A1F-536A-46C5-95D1-349AC3599BAEQ35827704-E9CDA8EB-9CC7-4B7D-A684-122EF058EFDCQ35876818-1F0A0096-6C02-41B3-AA8F-EA421A49907BQ36558384-F1A71955-0DE8-429F-99AB-098B26FA7100Q37418674-C9324F85-B0E2-4197-B1BA-560E7C8CBDB5Q37790384-AF6412F1-35F3-4744-B4CE-1FB508C7D29AQ46108030-BC9E965E-B549-4F20-9182-6567D98EA7A1Q46799921-32427AE1-061C-455D-B618-9A8A1A8C3BCA
P2860
The peroxisome proliferator-activated receptor alpha (PPARalpha) agonist ciprofibrate inhibits apolipoprotein B mRNA editing in low density lipoprotein receptor-deficient mice: effects on plasma lipoproteins and the development of atherosclerotic le
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
The peroxisome proliferator-ac ...... elopment of atherosclerotic le
@en
type
label
The peroxisome proliferator-ac ...... elopment of atherosclerotic le
@en
prefLabel
The peroxisome proliferator-ac ...... elopment of atherosclerotic le
@en
P2093
P2860
P356
P1476
The peroxisome proliferator-ac ...... elopment of atherosclerotic le
@en
P2093
Debnath Mukhopadhyay
Jayme Borensztajn
Nicholas O Davidson
P2860
P304
28662-28669
P356
10.1074/JBC.M403271200
P407
P577
2004-04-27T00:00:00Z